Sadowsky, Carl H., Dengiz, Alan, Olin, Jason T., Koumaras, Barbara, Meng, Xiangyi, Brannan, Stephen

Objective: Evaluate safety and tolerability of switching from donepezil to rivastigmine transdermal patch in patients with mild to moderate Alzheimer’s disease.; Methods: Prospective, parallel-group, open-label study to evaluate immediate or delayed switch from 5-10 mg/day donepezil to 4.6 mg/24 h rivastigmine following a 4-week treatment period.; Results: Rates of discontinuation due to any reason or […]

Grossberg, George, Sadowsky, Carl, Fröstl, Hans, Frölich, Lutz, Nagel, Jennifer, Tekin, Sibel, Zechner, Stefanie, Ros, Jacqueline, Orgogozo, Jean-Marc

The primary objective of the open-label extension was to evaluate the long-term safety and tolerability of a transdermal rivastigmine patch up to 1 year, as a novel approach to treatment in Alzheimer disease. This was a 28-week extension to a 24-week, double-blind, double-dummy, placebo-controlled, and active-controlled study evaluating rivastigmine patches [9.5 mg/24 h (10 cm2) […]

Olin, Jason T., Bhatnagar, Vinod, Reyes, Patricio, Koumaras, Barbara, Meng, Xiangyi, Brannan, Stephen

Objective: Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild-to-moderate Alzheimer’s disease (AD) and Parkinson’s disease dementia. Orally administered ChEIs may be associated with gastrointestinal (GI) side effects and add-on therapy with memantine, an N-methyl-d-aspartate receptor antagonist, approved for moderate-to-severe AD, may ameliorate such side effects. This was […]

Doody, Rachelle S., Ferris, Steven, Salloway, Stephen, Yijun, Sun, Goldman, Robert, Yikang, Xu, Gao, Jeff, Murthy, Anita K.

Following a 48-week, double-blind, randomized, placebo-controlled trial of donepezil in 821 patients with amnestic mild cognitive impairment (aMCI), safety and tolerability of donepezil (10 mg) were further evaluated in a 28-week extension study. Of 499 participants who completed the double-blind phase, 145 enrolled in the open-label study. Adverse events (AEs) were recorded throughout. Overall, 57.4% […]

Holl, Anna K., Wilkinson, Leonora, Painold, Annamaria, Holl, Etienne M., Bonelli, Raphael M.

Patients with Huntington’s disease (HD) often suffer from psychiatric symptoms including affective disorder, psychosis, irritability, and apathy, which may be present in all stages of the disease. However–despite the obvious likelihood that these symptoms may be reduced by antidepressive treatments–to date, the effectiveness of such treatments in HD has only ever been examined in case […]